DPC Dash Ltd Announces Full Year 2025 Financial Results

DPC Dash Ltd Announces Full Year 2025 Financial Results

Revenues increased to RMB5.38 billion, representing 24.8% year-over-year growth Adjusted net profit reached RMB187.9 million, representing 43.3% year-over-year growth Store-level operating profit grew by 18.5%; Adjusted group EBITDA increased by...

Kuaishou Technology Announces Fourth Quarter and Full Year 2025 Financial Results

Kuaishou Technology Announces Fourth Quarter and Full Year 2025 Financial Results

HONG KONG, March 25, 2026 /PRNewswire/ -- Kuaishou Technology ("Kuaishou" or the "Company"; HKD Counter Stock Code: 01024 / RMB Counter Stock Code: 81024), a leading content community and social platform, today announced its financial results for...

BrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States

BrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States

BGM0504 shown to be generally well tolerated Overall safety, pk, and efficacy profile supports once-daily oral dosing SUZHOU, China, March 25, 2026 /PRNewswire/ -- BrightGene Bio-Medical Technology Co., Ltd. (SSE: 688166, "BrightGene" or "the...

Baguio Green Group Announces 2025 Annual Results

Baguio Green Group Announces 2025 Annual Results

Profit surges 72% to HK$97 million Hits historical high since listing HONG KONG, March 25, 2026 /PRNewswire/ -- Baguio Green Group Limited (''Baguio'' or the ''Group'', Stock Code: 01397.HK) is pleased to announce its annual results for the year...

Hope Medicine Announces First Patient Dosed in the Phase III Clinical Trial for Endometriosis

Hope Medicine Announces First Patient Dosed in the Phase III Clinical Trial for Endometriosis

SHANGHAI, March 25, 2026 /PRNewswire/ -- Hope Medicine Inc., a science-driven, clinical-stage innovative biopharmaceutical company, announced that the first patient has been dosed in the Phase III clinical trial of HMI-115, its first-in-class...

Paranovus Entertainment Technology Limited Announces Pricing of $5 Million Registered Direct Offering At-The-Market Under NASDAQ Rules

Paranovus Entertainment Technology Limited Announces Pricing of $5 Million Registered Direct Offering At-The-Market Under NASDAQ Rules

NEW YORK, March 25, 2026 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ: PAVS) today announced that it has entered into a definitive agreement with a single institutional investor for a registered direct offering priced...

Fosun Pharma Announces 2025 Annual Results

Fosun Pharma Announces 2025 Annual Results

Innovation and Globalization Propel Fosun Pharma's High-Quality Growth SHANGHAI, March 24, 2026 /PRNewswire/ -- On 24 March, 2026, Fosun Pharma ("the company", stock code: 600196.SH; 02196.HK), an innovation-driven global pharmaceutical and...

Datasea (NASDAQ: DTSS) Announces Initial U.S. Commercial Rollout and Commercialization Pathway for Acoustic Technology-Enabled Wellness Care Robots

Datasea (NASDAQ: DTSS) Announces Initial U.S. Commercial Rollout and Commercialization Pathway for Acoustic Technology-Enabled Wellness Care Robots

Early-stage deployments across multiple U.S. regions expected to support initial service revenue generation and scalable commercialization model BEIJING, March 24, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a...

Cheetah Mobile Announces Fourth Quarter and Fiscal Year 2025 Unaudited Consolidated Financial Results

Cheetah Mobile Announces Fourth Quarter and Fiscal Year 2025 Unaudited Consolidated Financial Results

AI and Others revenue grew 84.7% year over year and accounted for 46.5% of total revenue in 2025 BEIJING, March 24, 2026 /PRNewswire/ -- Cheetah Mobile Inc. ("Cheetah Mobile" or the "Company") (NYSE: CMCM), a China-based IT company with a commitment...

DualityBio (9606.HK) Announces 2025 Annual Results

DualityBio (9606.HK) Announces 2025 Annual Results

HONG KONG, March 24, 2026 /PRNewswire/ -- Duality Biotherapeutics, Inc. (Hong Kong Stock Exchange Code: 09606.HK, hereinafter referred to as "DualityBio" or the "Company"), a leading global clinical-stage innovative biopharmaceutical company, today...

  • 1
  • ...
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • ...
  • 52
  • menu
    menu